Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib Rechallenge in HER2+ Metastatic Breast Cancer
NCT05346861Phase 3Unknown
- Sponsor
- Fudan University
- Start
- Sep 2021
- Primary completion
- Oct 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pyrotinib in HER2-positive metastatic breast cancer (2 arms), sponsored by Fudan University. Primary endpoint: Progression Free Survival at 8 months. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT05346861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05346861.